Clinical trial
A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS).
NCT06100276 is registered in ClinicalTrials.gov with UniQure Biopharma B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS).
- Lead sponsor
- UniQure Biopharma B.V.
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- August 1, 2024
- Completion date
- June 30, 2031
- Enrollment
- 20 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.